Lybalvi (Olanzapine/Samidorphan Malate) Patent Expiration, LOE Window & CMS Spending

Lybalvi (Olanzapine/Samidorphan Malate) by Alkermes: FDA Orange Book core substance LOE 2031-08-30 (last listed 2041-11-12), 0 AB generics, $284.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlkermes
FDA Application & PathwayN213378 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-08-30
Last Listed Patent or Exclusivity Date2041-11-12
Orange Book Patents (*PED Extensions)14 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$284.6M
2024 Medicare Part D Spend$127.3M
2024 Medicaid Spend$157.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.